-- Total global revenues of $1.9 billion for the third quarter, an
increase of 34% from the prior year
-- BRUKINSA (zanubrutinib) global revenues of $1.4 billion for the third
quarter, an increase of 34% from the prior year
-- Diluted GAAP Earnings per American Depository Share (ADS) of $3.28 for
the third quarter; non-GAAP diluted Earnings per ADS of $4.59 for the
third quarter
-- Raised 2026 total revenue guidance to $6.9 to $7.0 billion; GAAP
operating income of $1.2 to $1.3 billion, non-GAAP operating income of
$1.9 to $2.0 billion
SAN CARLOS, Calif.--(BUSINESS WIRE)--November 05, 2026--
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced financial results and corporate updates from the third quarter of 2026.
John V. Oyler, Co-Founder, Chairman, and CEO, BeOne, said:
"Our strong third quarter results and raised full-year guidance reflect continued rapid global growth and leadership in hematology, anchored by our foundational BTK inhibitor BRUKINSA, which drives powerful and sustained responses in patients, and now joined by our next-generation BCL2 inhibitor BEQALZI. We look forward to multiple catalysts in the coming months from one of the deepest pipelines in oncology, spanning hematology and solid tumors, accelerated by our differentiated capabilities in R&D, manufacturing, and commercialization."
(Amounts in thousands of U.S. dollars and unaudited)
Three Months Ended Nine Months Ended
September 30, September 30,
---------------------- ----------------------
2026 2025 % Change 2026 2025 % Change
---------- ---------- ---------- ---------- ---------- ----------
Net product
revenues $1,855,057 $1,395,013 33% $5,022,180 $3,805,619 32%
Other revenue $ 34,758 $ 17,271 101% $ 86,144 $ 39,244 120%
--------- --------- --------- ---------
Total revenue $1,889,815 $1,412,284 34% $5,108,324 $3,844,863 33%
GAAP income
from
operations $ 418,675 $ 163,114 157% $ 993,624 $ 262,101 279%
Adjusted
income from
operations* $ 612,226 $ 341,184 79% $1,529,649 $ 755,486 102%
GAAP net
income $ 384,706 $ 124,841 208% $ 849,070 $ 220,431 285%
Adjusted net
income* $ 538,735 $ 303,663 77% $1,358,274 $ 692,622 96%
GAAP basic
EPS per ADS $ 3.38 $ 1.13 199% $ 7.58 $ 2.03 273%
Adjusted
basic EPS
per ADS* $ 4.74 $ 2.76 72% $ 12.12 $ 6.38 90%
GAAP diluted
EPS per ADS $ 3.28 $ 1.09 201% $ 7.30 $ 1.96 272%
Adjusted
diluted EPS
per ADS* $ 4.59 $ 2.65 73% $ 11.68 $ 6.14 90%
Free Cash
Flow* $ 473,532 $ 354,469 34% $1,069,423 $ 561,916 90%
*For an explanation of our use of non-GAAP financial measures, refer to the "Note
Regarding Use of Non-GAAP Financial Measures" section later in this press release and
for a reconciliation of each non-GAAP financial measure to the most comparable GAAP
measures, see the table at the end of this press release.
Third Quarter 2026 Financial Results
Product Revenue totaled $1.9 billion for the third quarter of 2026, representing growth of 33% compared to the prior-year period.
-- BRUKINSA: Global sales totaled $1.4 billion for the third quarter of
2026, representing growth of 34% compared to the prior-year period; U.S.
sales of BRUKINSA totaled $1.0 billion in the third quarter of 2026,
representing growth of 36% compared to the prior-year period.
-- TEVIMBRA (tislelizumab): Global sales totaled $243 million in the third
quarter of 2026, representing growth of 28% compared to the prior-year
period.
-- Amgen in-licensed products: Global sales totaled $167 million in the
third quarter of 2026, representing growth of 26% compared to the
prior-year period.
Gross Margin as a percentage of global product sales for the third quarter of 2026 was 88%, compared to 86% in the prior-year period on a GAAP basis. The gross-margin percentage increased due to a proportionally higher sales mix of global BRUKINSA compared to other products in the Company's portfolio. Gross margin also benefited from productivity improvements resulting in lower costs for both BRUKINSA and TEVIMBRA, which was offset by a non-cash intangible asset impairment charge of $22 million associated with our decision to discontinue promotion of POBEVCY. On an adjusted basis, which does not include depreciation and amortization, or the impairment charge, gross margin as a percentage of product sales increased to 90%, from 86% in the comparable period of the prior year.
Operating Expenses
The following table summarizes operating expenses for the third quarter of 2026:
GAAP Non-GAAP
---------------------- --------------------
(unaudited, in
thousands,
except
percentages) Q3 2026 Q3 2025 % Change Q3 2026 Q3 2025 % Change
---------- ---------- ---------- ---------- -------- ----------
Research and
development $ 660,784 $ 523,662 26% $ 586,168 $445,904 31%
Selling, general
and
administrative $ 593,460 $ 528,998 12% $ 503,719 $434,484 16%
--------- --------- --------- -------
Total operating
expenses $1,254,244 $1,052,660 19% $1,089,887 $880,388 24%
--------- --------- --------- -------
The following table summarizes operating expenses for the year-to-date period ended September 30, 2026, and 2025:
GAAP Non-GAAP
---------------------- ----------------------
(unaudited, in
thousands,
except Q3 YTD Q3 YTD Q3 YTD Q3 YTD
percentages) 2026 2025 % Change 2026 2025 % Change
---------- ---------- ---------- ---------- ---------- ----------
Research and
development $1,814,288 $1,530,445 19% $1,586,022 $1,311,156 21%
Selling, general
and
administrative $1,741,771 $1,526,199 14% $1,476,386 $1,271,650 16%
--------- --------- --------- ---------
Total operating
expenses $3,556,059 $3,056,644 16% $3,062,408 $2,582,806 19%
--------- --------- --------- ---------
Research and Development (R&D) Expenses increased for the third quarter of 2026 compared to the prior-year period on both a GAAP and adjusted basis due to advancing early clinical programs into late stage and preclinical programs into the clinic.
Selling, General and Administrative (SG&A) Expenses increased for the third quarter of 2026 compared to the prior-year period on both a GAAP and adjusted basis due to continued investment to support commercial growth.
Net Income and Basic/Diluted Earnings Per Share
GAAP net income for the third quarter of 2026 was $385 million, an increase of $260 million over the prior-year period, primarily attributable to revenue growth and improved operating leverage. Adjusted net income was $539 million, an increase of $235 million over the prior-year period.
For the third quarter of 2026, basic and diluted earnings per share were $0.26 and $0.25 per share and $3.38 and $3.28 per American Depositary Share (ADS), respectively, compared to $0.09 and $0.08 per share and $1.13 and $1.09 per ADS in the prior-year period. On an adjusted basis, basic and diluted earnings per share was $0.36 and $0.35 per share and $4.74 and $4.59 per ADS, respectively, compared to $0.21 and $0.20 per share and $2.76 and $2.65 per ADS in the prior-year period.
Free Cash Flow for the third quarter of 2026 was $474 million, representing an increase of $119 million over the prior-year period.
For further details on BeOne's Third Quarter 2026 Financial Statements, please see BeOne's Quarterly Report on Form 10-Q for the third quarter of 2026 filed with the U.S. Securities and Exchange Commission.
Full Year 2026 Guidance
BeOne's financial guidance is summarized below:
Prior FY 2026 Guidance Current FY 2026
Guidance(1)
Total revenue $6.6B - $6.8B $6.9B - $7.0B
GAAP gross margin % High-80% range High-80% range
GAAP operating expenses(2) $4.8B - $5.0B $4.9B - $5.0B
(combined R&D and SG&A)
GAAP operating income(2) $1.0B - $1.1B $1.2B - $1.3B
Non-GAAP operating $1.7B-$1.8B $1.9B-$2.0B
income(2,3)
(1) Assumes November 1, 2026, foreign exchange rates.
(2) Does not assume any potential new, material business development activity
or unusual/non-recurring items.
(3) Non-GAAP operating income is a financial measure that excludes from the
corresponding GAAP measure costs related to share-based compensation,
depreciation and amortization expense. Guidance assumes that Non-GAAP expenses
track overall expense growth.
BeOne's total revenue guidance for full year 2026 of $6.9 billion to $7.0 billion reflects performance through the third quarter and the Company's expectations for the remainder of the year. Gross margin percentage is expected to be in the high-80% range and includes the impact of product mix and productivity improvements. Guidance for combined operating expenses on a GAAP basis includes expectations of investment to support growth.
The Company is providing the following additional guidance on items impacting net income and earnings per ADS:
-- Other income (expense): Estimated range of $25 million to $50 million
in expense, includes interest amortization from the Royalty Pharma
arrangement.
-- Income tax outlook: Earnings may provide sufficient positive evidence
to reverse certain valuation allowances in 2026, resulting in a material
tax benefit when recognized. The Company continues to evaluate and assess
the magnitude but expects the reversal will occur in the fourth quarter
of 2026. See Form 10-Q for additional updates.
-- Diluted ADS outstanding: The Company expects diluted ADSs outstanding
of approximately 118 million.
Third Quarter 2026 Business Highlights
Core Marketed Products
BRUKINSA (zanubrutinib)
-- Received U.S. Food and Drug Administration (FDA) Priority Review
designation for the Phase 3 MANGROVE filing
-- Completed Phase 3 MANGROVE regulatory submissions in the EU and China.
-- 29 abstracts accepted for presentation at the American Society of
Hematology (ASH) 2026 Annual Meeting, including interim analysis results
from the Phase 3 MANGROVE study in first-line mantle cell lymphoma (MCL)
to be presented during the Plenary Scientific Session.
BEQALZI (sonrotoclax)
-- 10 abstracts accepted for presentation at ASH 2026.
TEVIMBRA (tislelizumab)
-- Received Japan regulatory approval for the treatment of adult patients
with first-line nasopharyngeal cancer.
ZIIHERA (zanidatamab) for which BeOne holds commercialization rights in select markets
-- Presented Phase 3 survival data reinforcing benefit of
ZIIHERA-containing regimens in first-line HER2+ gastroesophageal
adenocarcinoma (GEA) at the European Society for Medical Oncology
Congress 2026 (ESMO 2026).
-- Received U.S. Food and Drug Administration (FDA) approval for
TEVIMBRA-based regimen for first-line HER2+ GEA.
Select Clinical-Stage Programs
Hematology
-- 6 Tacabrutideg abstracts accepted for presentation at ASH 2026.
-- Tacabrutideg (BTK CDAC): Pivotal Phase 2 portion of CaDAnCe-101 met its
primary endpoint of overall response rate in patients with
relapsed/refractory chronic lymphocytic leukemia (CLL).
-- BG-75202 (KAT6 A/B inhibitor): First patient enrolled into monotherapy
cohort for the Phase 1 study for the treatment of adult patients with
acute myeloid leukemia.
Gastrointestinal Cancers
-- BGB-B2033 (GPC3x4-1BB bispecific antibody):
-- Updated data presented at ESMO 2026.
-- Received Orphan Drug Designation from the European Commission
and awarded Innovation Passport, enabling entry to the UK's
Innovative Licensing and Access Pathway, in hepatocellular
carcinoma $(HCC)$.
-- BG-85738 (RAS ONi): First patient enrolled in the Phase 1 study of
advanced solid tumors with RAS mutations.
Lung Cancer
-- BG-C477 (CEA ADC):
-- Disclosed first clinical data at ESMO 2026.
-- Received FDA Fast Track Designation for the treatment of
patients with advanced or metastatic CEA-high non-small cell lung
cancer whose disease has progressed following prior systemic
therapy.
-- BGB 58067 (MTA-cooperative PRMT5 inhibitor): Disclosed first clinical
data at ESMO 2026.
Breast and Gynecological Cancers
-- BG-C9074 (B7-H4 ADC): Initiated Starstone-301 Phase 3 study in
combination with bevacizumab for the treatment of adult patients with
first-line ovarian cancer in maintenance setting.
Anticipated R&D Milestones
Programs Milestones Timing
--------------------------------- --------------------------------- --------
BRUKINSA Regulatory submission in Japan Q4 2026
for the treatment of adult
patients with first-line MCL.
TEVIMBRA China regulatory action for the
treatment of adult patients with 1H 2027
first-line HER2-positive GEA in
combination with ZIIHERA and
chemotherapy.
ZIIHERA China regulatory action for the 1H 2027
treatment of adult patients with
first-line HER2-positive GEA in
combination with chemotherapy,
with or without TEVIMBRA.
Tacabrutideg Phase 2 potential submission for Mid 2027
(BGB-16673) the treatment of adult patients
with R/R CLL.
CaDAnCe-306: Phase 3 study 1H 2027
initiation for R/R CLL in
combination with BEQALZI
GroundBBreaker-301 Phase 3 study Q4 2026
initiation in second-line or
later HCC.
BGB-B2033 GroundBBreaker-201 potentially Q4 2026
(GPC3x4-1BB bispecific antibody) pivotal single-arm Phase 2 study
initiation in second-line or
later HCC.
GroundBBreaker-302 pivotal Phase 1H 2027
3 study initiation in first-line
HCC.
Corporate Updates
-- Announced a multi-part collaboration with Revolution Medicines, including a clinical collaboration to evaluate drug combinations incorporating select clinical-stage oncology assets from BeOne with any of Revolution Medicines' four clinical RAS(ON) inhibitors, and a separate regional rights agreement granting BeOne exclusive development and commercialization rights to these Revolution Medicines assets in select Asian markets. -- Announced a voluntary agreement with the U.S. Government to expand access to innovative cancer medicines for American patients while strengthening the Company's U.S manufacturing footprint. -- Announced the renewal of a partnership with the BeOne Care Foundation and The Max Foundation, a leading global health nonprofit organization, to expand access to BRUKINSA for the treatment of adult patients with CLL in low- and middle-income countries through 2028.
BeOne's Earnings Results Webcast
The Company's earnings conference call for the third quarter 2026 will be broadcast via webcast at 8:00 a.m. ET on Thursday, November 5, 2026, and will be accessible through the Investors section of BeOne's website at www.beonemedicines.com. Supplemental information in the form of a slide presentation, transcript of prepared remarks, and a replay of the webcast will also be available.
About BeOne
BeOne Medicines is a global oncology company that is discovering and developing innovative treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The Company has a growing global team spanning six continents who are driven by scientific excellence and exceptional speed to reach more patients than ever before.
To learn more about BeOne, please visit www.beonemedicines.com and follow us on LinkedIn, X, Facebook and Instagram.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding: BeOne's continued rapid global growth and leadership in hematology; future catalysts for BeOne's business; BeOne's full year 2026 guidance; BeOne's expectations regarding certain valuation allowances; BeOne's expectations regarding continued global expansion and investment to support growth; upcoming R&D milestones to be achieved by BeOne; the timing of clinical and regulatory developments and data readouts; and BeOne's plans, commitments, aspirations and goals under the caption "About BeOne." Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeOne's ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; BeOne's ability to achieve commercial success for its marketed medicines and drug candidates, if approved; BeOne's ability to obtain and maintain protection of intellectual property for its medicines and technology; BeOne's reliance on third parties to conduct drug development, manufacturing, commercialization, and other services; BeOne's limited experience in obtaining regulatory approvals and commercializing pharmaceutical products; BeOne's ability to obtain additional funding for operations and to complete the development of its drug candidates and achieve and maintain profitability; and those risks more fully discussed in the section entitled "Risk Factors" in BeOne's most recent periodic report filed with the U.S. Securities and Exchange Commission ("SEC"), as well as discussions of potential risks, uncertainties, and other important factors in BeOne's subsequent filings with the SEC. All information in this press release is as
of the date of this press release, and BeOne undertakes no duty to update such information unless required by law. BeOne's financial guidance is based on estimates and assumptions that are subject to significant uncertainties.
Condensed Consolidated Statements of Operations (U.S. GAAP)
(Amounts in thousands of U.S. dollars, except for shares, American Depositary Shares (ADSs),
per share and per ADS data)
Three Months Ended Nine Months Ended
September 30, September 30,
-------------------------------- ----------------------------------
2026 2025 2026 2025
------------- ------------- ------------- -------------
(Unaudited) (Unaudited)
Revenues
Product revenue,
net $ 1,855,057 $ 1,395,013 $ 5,022,180 $ 3,805,619
Other revenue 34,758 17,271 86,144 39,244
------------- ------------- ------------- -------------
Total revenues 1,889,815 1,412,284 5,108,324 3,844,863
Cost of sales -
products 216,896 196,510 558,641 526,118
------------- ------------- ------------- -------------
Gross profit 1,672,919 1,215,774 4,549,683 3,318,745
Operating expenses:
Research and
development 660,784 523,662 1,814,288 1,530,445
Selling, general
and
administrative 593,460 528,998 1,741,771 1,526,199
------------- ------------- ------------- -------------
Total operating
expenses 1,254,244 1,052,660 3,556,059 3,056,644
------------- ------------- ------------- -------------
Income from operations 418,675 163,114 993,624 262,101
Interest income 33,663 19,393 89,227 43,735
Interest expense (42,407) (16,364) (115,033) (31,361)
Other income
(expense), net 429 (18,979) 14,216 (6,862)
------------- ------------- ------------- -------------
Income before income
taxes 410,360 147,164 982,034 267,613
Income tax expense 25,654 22,323 132,964 47,182
------------- ------------- ------------- -------------
Net income $ 384,706 $ 124,841 $ 849,070 $ 220,431
============= ============= ============= =============
Earnings per share
Basic $ 0.26 $ 0.09 $ 0.58 $ 0.16
============= ============= ============= =============
Diluted $ 0.25 $ 0.08 $ 0.56 $ 0.15
============= ============= ============= =============
Weighted-average
shares
outstanding--basic 1,478,074,394 1,432,801,699 1,457,134,424 1,410,497,062
============= ============= ============= =============
Weighted-average
shares
outstanding--diluted 1,524,954,790 1,488,750,354 1,511,972,953 1,465,535,004
============= ============= ============= =============
Earnings per American
Depositary Share
("ADS")
Basic $ 3.38 $ 1.13 $ 7.58 $ 2.03
============= ============= ============= =============
Diluted $ 3.28 $ 1.09 $ 7.30 $ 1.96
============= ============= ============= =============
Weighted-average ADSs
outstanding--basic 113,698,030 110,215,515 112,087,263 108,499,774
============= ============= ============= =============
Weighted-average ADSs
outstanding--diluted 117,304,215 114,519,258 116,305,612 112,733,462
============= ============= ============= =============
Select Condensed Consolidated Balance Sheet Data (U.S. GAAP)
(Amounts in thousands of U.S. Dollars)
As of
-------------------------------
September 30, December 31,
2026 2025
--------------- --------------
(unaudited) (audited)
Assets:
Cash, cash equivalents and restricted
cash $ 5,866,314 $ 4,609,647
Accounts receivable, net 1,092,535 865,080
Inventories 807,922 608,227
Property, plant and equipment, net 1,647,231 1,641,678
Total assets $ 9,875,925 $ 8,188,573
Liabilities and equity:
Accounts payable $ 496,879 $ 479,035
Accrued expenses and other payables 1,342,646 1,109,120
R&D cost share liability -- 64,345
Sale of future royalty liability 912,581 906,956
Debt 1,074,081 1,019,206
Total liabilities 4,055,531 3,827,379
Total equity $ 5,820,394 $ 4,361,194
Select Condensed Consolidated Statements of Cash Flows (U.S. GAAP)
(Amounts in thousands of U.S. Dollars)
Three Months Ended Nine Months Ended
September 30, September 30,
------------------------ --------------------------
2026 2025 2026 2025
--------- --------- --------- ---------
(unaudited) (unaudited)
Cash, cash
equivalents and
restricted cash at
beginning of
period $5,280,674 $2,786,086 $4,609,647 $2,638,747
Net cash provided
by operating
activities 508,707 402,553 1,172,863 710,233
Net cash used in
investing
activities (35,760) (49,274) (130,623) (237,820)
Net cash provided
by financing
activities 102,194 961,272 164,772 962,520
Net effect of
foreign exchange
rate changes 10,499 9,905 49,655 36,862
--------- --------- --------- ---------
Net increase
in cash, cash
equivalents,
and
restricted
cash 585,640 1,324,456 1,256,667 1,471,795
--------- --------- --------- ---------
Cash, cash
equivalents and
restricted cash at
end of period $5,866,314 $4,110,542 $5,866,314 $4,110,542
========= ========= ========= =========
Note Regarding Use of Non-GAAP Financial Measures
BeOne provides certain non-GAAP financial measures, including Adjusted Cost of Sales- Product, Adjusted Operating Expenses, Adjusted Income from Operations, Adjusted Income Tax Expense, Adjusted Net Income, Adjusted Earnings Per Share, Free Cash Flow and certain other non-GAAP income statement line items, each of which include adjustments to GAAP figures. These non-GAAP financial measures are intended to provide additional information on BeOne's operating performance. Adjustments to BeOne's GAAP figures exclude, as applicable, non-cash items such as share-based compensation, depreciation and amortization. Certain other special items or substantive events may also be included in the non-GAAP adjustments periodically when their magnitude is significant within the periods incurred. Non-GAAP adjustments are tax effected to the extent there is U.S. GAAP current tax expense. The Company currently records a valuation allowance on its net deferred tax assets, so there is no net impact recorded for deferred tax effects. BeOne maintains an established non-GAAP policy that guides the determination of what costs will be excluded in non-GAAP financial measures and the related protocols, controls and approval with respect to the use of such measures. BeOne believes that these non-GAAP financial measures, when considered together with the GAAP figures, can enhance an overall understanding of BeOne's operating performance. The non-GAAP financial measures are included with the intent of providing investors with a more complete understanding of BeOne's historical and expected financial results and trends and to facilitate comparisons between periods and with respect to projected information. In addition, these non-GAAP financial measures are among the indicators BeOne's management uses for planning and forecasting purposes and measuring BeOne's performance. These non-GAAP financial measures should be considered in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. The non-GAAP financial measures used by BeOne may be calculated differently
from, and therefore may not be comparable to, non-GAAP financial measures used by other companies.
RECONCILIATION OF SELECTED GAAP MEASURES TO NON-GAAP MEASURES
(Amounts in thousands of U.S. Dollars, except for per share and per ADS
data)
(unaudited)
Three Months Ended Nine Months Ended
September 30, September 30,
------------------------ --------------------------
2026 2025 2026 2025
--------- --------- --------- ---------
Reconciliation
of GAAP to
adjusted cost of
sales -
products:
GAAP cost of
sales -
products $ 216,896 $ 196,510 $ 558,641 $ 526,118
Less:
Depreciation 5,596 4,261 15,442 10,195
Less:
Amortization of
intangibles 23,598 1,537 26,932 8,459
Less: Other -- -- -- 893
--------- --------- --------- ---------
Adjusted cost of
sales -
products $ 187,702 $ 190,712 $ 516,267 $ 506,571
========= ========= ========= =========
Reconciliation
of GAAP to
adjusted
research and
development:
GAAP research and
development $ 660,784 $ 523,662 $1,814,288 $1,530,445
Less: Share-based
compensation
cost 56,474 58,839 168,866 164,998
Less:
Depreciation 18,142 18,919 59,400 54,291
--------- --------- --------- ---------
Adjusted research
and development $ 586,168 $ 445,904 $1,586,022 $1,311,156
========= ========= ========= =========
Reconciliation
of GAAP to
adjusted
selling, general
and
administrative:
GAAP selling,
general and
administrative $ 593,460 $ 528,998 $1,741,771 $1,526,199
Less: Share-based
compensation
cost 76,143 81,947 224,566 221,792
Less:
Depreciation 13,582 12,550 40,769 32,712
Less:
Amortization of
intangibles 16 17 50 45
--------- --------- --------- ---------
Adjusted selling,
general and
administrative $ 503,719 $ 434,484 $1,476,386 $1,271,650
========= ========= ========= =========
Reconciliation
of GAAP to
adjusted
operating
expenses:
GAAP operating
expenses $1,254,244 $1,052,660 $3,556,059 $3,056,644
Less: Share-based
compensation
cost 132,617 140,786 393,432 386,790
Less:
Depreciation 31,724 31,469 100,169 87,003
Less:
Amortization of
intangibles 16 17 50 45
--------- --------- --------- ---------
Adjusted
operating
expenses $1,089,887 $ 880,388 $3,062,408 $2,582,806
========= ========= ========= =========
Reconciliation
of GAAP to
adjusted income
from
operations:
GAAP income from
operations $ 418,675 $ 163,114 $ 993,624 $ 262,101
Plus: Share-based
compensation
cost 132,617 140,786 393,432 386,790
Plus:
Depreciation 37,320 35,730 115,611 97,198
Plus:
Amortization of
intangibles 23,614 1,554 26,982 8,504
Plus: Other -- -- -- 893
--------- --------- --------- ---------
Adjusted income
from operations $ 612,226 $ 341,184 $1,529,649 $ 755,486
========= ========= ========= =========
Reconciliation
of GAAP to
adjusted income
tax expense:
GAAP income tax
expense $ 25,654 $ 22,323 $ 132,964 $ 47,182
Plus: Discrete
tax items 11,527 926 (41,847) 9,663
Plus: Income tax
effect of
non-GAAP
adjustments 27,995 17,044 68,668 45,747
--------- --------- --------- ---------
Adjusted income
tax expense $ 65,176 $ 40,293 $ 159,785 $ 102,592
========= ========= ========= =========
Reconciliation
of GAAP to
adjusted net
income:
GAAP net income $ 384,706 $ 124,841 $ 849,070 $ 220,431
Plus: Share-based
compensation
expenses 132,617 140,786 393,432 386,790
Plus:
Depreciation 37,320 35,730 115,611 97,198
Plus:
Amortization of
intangibles 23,614 1,554 26,982 8,504
Plus: Other -- -- -- 893
Plus: Impairment
of equity
investments -- 18,722 -- 34,216
Plus: Discrete
tax items (11,527) (926) 41,847 (9,663)
Plus: Income tax
effect of
non-GAAP
adjustments(1) (27,995) (17,044) (68,668) (45,747)
--------- --------- --------- ---------
Adjusted net
income $ 538,735 $ 303,663 $1,358,274 $ 692,622
========= ========= ========= =========
Reconciliation
of GAAP to
adjusted EPS -
basic
GAAP earnings per
share - basic $ 0.26 $ 0.09 $ 0.58 $ 0.16
Plus: Share-based
compensation
expenses 0.09 0.10 0.27 0.27
Plus:
Depreciation 0.03 0.02 0.08 0.07
Plus:
Amortization of
intangibles 0.02 0.00 0.02 0.01
Plus: Other 0.00 0.00 0.00 0.00
Plus: Impairment
of equity
investments 0.00 0.01 0.00 0.02
Plus: Discrete
tax items (0.01) 0.00 0.03 (0.01)
Plus: Income tax
effect of
non-GAAP
adjustments(1) (0.02) (0.01) (0.05) (0.03)
--------- --------- --------- ---------
Adjusted earnings
per share -
basic $ 0.36 $ 0.21 $ 0.93 $ 0.49
========= ========= ========= =========
Reconciliation
of GAAP to
adjusted EPS -
diluted
GAAP earnings per
share - diluted $ 0.25 $ 0.08 $ 0.56 $ 0.15
Plus: Share-based
compensation
expenses 0.09 0.09 0.26 0.26
Plus:
Depreciation 0.02 0.02 0.08 0.07
Plus:
Amortization of
intangibles 0.02 0.00 0.02 0.01
Plus: Other 0.00 0.00 0.00 0.00
Plus: Impairment
of equity
investments 0.00 0.01 0.00 0.02
Plus: Discrete
tax items (0.01) 0.00 0.03 (0.01)
Plus: Income tax
effect of
non-GAAP
adjustments(1) (0.02) (0.01) (0.05) (0.03)
--------- --------- --------- ---------
Adjusted earnings
per share -
diluted $ 0.35 $ 0.20 $ 0.90 $ 0.47
========= ========= ========= =========
Reconciliation
of GAAP to
adjusted
earnings per ADS
- basic
GAAP earnings per
ADS - basic $ 3.38 $ 1.13 $ 7.58 $ 2.03
Plus: Share-based
compensation
expenses 1.17 1.28 3.51 3.56
Plus:
Depreciation 0.33 0.32 1.03 0.90
Plus:
Amortization of
intangibles 0.21 0.01 0.24 0.08
Plus: Other 0.00 0.00 0.00 0.01
Plus: Impairment
of equity
investments 0.00 0.17 0.00 0.32
Plus: Discrete
tax items (0.10) (0.01) 0.37 (0.09)
Plus: Income tax
effect of
non-GAAP
adjustments(1) (0.25) (0.15) (0.61) (0.42)
--------- --------- --------- ---------
Adjusted earnings
per ADS - basic $ 4.74 $ 2.76 $ 12.12 $ 6.38
========= ========= ========= =========
Reconciliation
of GAAP to
adjusted
earnings per ADS
- diluted
GAAP earnings per
ADS - diluted $ 3.28 $ 1.09 $ 7.30 $ 1.96
Plus: Share-based
compensation
expenses 1.13 1.23 3.38 3.43
Plus:
Depreciation 0.32 0.31 0.99 0.86
Plus:
Amortization of
intangibles 0.20 0.01 0.23 0.08
Plus: Other 0.00 0.00 0.00 0.01
Plus: Impairment
of equity
investments 0.00 0.16 0.00 0.30
Plus: Discrete
tax items (0.10) (0.01) 0.36 (0.09)
Plus: Income tax
effect of
non-GAAP
adjustments(1) (0.24) (0.15) (0.59) (0.41)
--------- --------- --------- ---------
Adjusted earnings
per ADS -
diluted $ 4.59 $ 2.65 $ 11.68 $ 6.14
========= ========= ========= =========
Tax effect of Non-GAAP adjustments is based on the statutory tax rate
in the relevant tax jurisdiction. Please note that the Company
currently records a valuation allowance on its net deferred tax assets,
so there is no net impact recorded for deferred tax effects.
Three Months Ended Nine Months Ended
September 30, September 30,
-------------------- -------------------------
2026 2025 2026 2025
------- ------- --------- --------
Free Cash
Flow
(Non-GAAP):
Net cash
provided by
operating
activities
(GAAP) $508,707 $402,553 $1,172,863 $ 710,233
Less:
Purchases of
property,
plant and
equipment (35,175) (48,084) (103,440) (148,317)
------- ------- --------- --------
Free Cash
Flow
(Non-GAAP) $473,532 $354,469 $1,069,423 $ 561,916
======= ======= ========= ========
Reconciliation of GAAP Operating Income Guidance
to Non-GAAP
Operating Income Guidance for Full Year 2026
(Unaudited)
GAAP operating income 1,200,000 -- 1,300,000
Plus: Adjustments to arrive at Non-GAAP(1) 700,000 -- 700,000
--------- ---------
Non-GAAP operating income 1,900,000 -- 2,000,000
========= =========
The non-GAAP adjustments are based on actual results through the first
nine months of 2026 and best available information at this time related to
similar items for the remainder of the year.
View source version on businesswire.com: https://www.businesswire.com/news/home/20261105790053/en/
CONTACT: Investor Contact
Liza Heapes
+1 857-302-5663
ir@beonemed.com
Media Contact
Meredith Ferguson
+1 216-338-3797
media@beonemed.com
Comments